Skip to main content
SpringerLink
Log in

Evaluation and Role of Single Chemotherapeutic Agents in Adult Non-Hodgkin’s Lymphoma

  • Chapter
Book cover Lymphoid Neoplasias II

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 65))

Abstract

The non-Hodgkin’s lymphomas are uniquely responsive to a broad range of chemotherapeutic agents of diverse chemical structure and mechanism of action. In the past decade, significant advances in histological diagnosis [86] and staging [20] have occurred documenting the importance of histology, nodal architecture, and stage upon intrinsic prognosis. Parallel to this, aggressive combination therapy has evolved and improved the prognosis in several subtypes, notably diffuse histiocytic and nodular mixed lymphocytic histiocytic lymphomas [15, 1]. In spite of these therapeutic advances, the majority of patients with non-Hodgkin’s lymphoma relapse and ultimately die. The purpose of this review is to reexamine the role of old and new drugs. Combination programs will be mentioned in an illustrative fashion; however, the emphasis will be on single agent activity and its relevance for future investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adamson R. H., Canellos, G. P., Sieber, S. M.: Studies on the antitumor activity of gallium nitrate (NSC 15200) and other Group Ill-a metal salts. Cancer Chemother. Rep. 59, 599–610 (1975)

    PubMed  Google Scholar 

  2. Alberto P., Gangji, D., Kenis, Y., Brugarolas, A., Clarysse, A., Sylvester, R., (EORTC Early Clinical Trials Group): Phase II Study of anhydro-ara-5 fluorocytidine (AAFC). Proc. AACR and ASCO 18, 231 (AACR abs. 923) (1977)

    Google Scholar 

  3. Altman S. J., Fletcher, W. S., Andrews, N. C., Wilson, W. L., Pischer, T.: Yoshi 864, a new Phase I study. Cancer 35,1145–1147 (1975)

    Article  PubMed  CAS  Google Scholar 

  4. Anderson T., De Vita, V., Bender, R., Mann, R., Chabner, B., Young, R.: Nodular lymphomas (NL): an important correlation of survival with complete remission induction. Proc. AACR and ASCO 18, 326 (ASCO abstr. C 238) (1977)

    Google Scholar 

  5. Andrews N. C., Weiss, A. J., Wilson, W., Nealon, T.: Phase II study of dibromodulcitol (NSC 104800). Cancer Chemother. Rep. 58,653–660 (1974)

    PubMed  CAS  Google Scholar 

  6. Baker L. J., Samson, M. K., Izbicki, R. M.: Phase I and II evaluation of cytembena in disseminated epithelial ovarian cancers and sarcomas. Cancer Treat. Rep. 60, (9), 1389–1391 (Sept. 1976)

    PubMed  CAS  Google Scholar 

  7. Beer C. T., Kajiwara, K., Mueller, G. C.: Synchronization of HeLa cells with 2,3-dihydro-lH- imidazo (l,2-b)-pyrazole. Biochem. Pharmacol, 23,1112–1115 (1974)

    Article  Google Scholar 

  8. Benjamin R. S., Hall, S. W., Burgess, M. A., Wheeler, W. L., Murphy, W. K., Blumenschein, G. R., Gottlieb, J. A.: A pharmacokinetically based Phase I-II study of single dose actinomycin D (NSC 3053). Cancer Treat. Rep. 60,289–291 (1976)

    PubMed  CAS  Google Scholar 

  9. Berd D., Cornog, J., Di Conti, R., Levitt, M., Bertino, J. R.,: Long term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 55, 1050–1054 (1975)

    Article  Google Scholar 

  10. Bergsagel D. E., Cowan, D. H., Hasselback, R.: Plasma cell myeloma: response of melphalan- resistant patients to high dose intermittent cyclophosphamide. Can. Med. Assoc. J. 107, 851–855 (1972)

    PubMed  CAS  Google Scholar 

  11. Bernard J., Jacquillat, Cl., Boiron, M., Weil, M., German, M. F., Izrael, V., Schaison, G., Delobel, J.: Cinquante-Sept. observations de leucemies aiques. Essai de traitmente par un derive semi-synthetique de la daunorubicine: le 22050 R.P. Nouv. Presse Med. 1, 2149–2152 (1972)

    PubMed  CAS  Google Scholar 

  12. Blom J. and Cancer and Leukemia Group B: Treatment of stage II & IV diffuse lymphocytic and histiocytic lymphoma with vincristine/prednisone/bleomycin/streptonigrin induction, cyclophosphamide/vincristine/prednisone maintenance with and without consolidation with vinblastine/ CCNU/prednisone. Proc. AACR and ASCO 18, 332 (ASCO abstr. C-261) (1977)

    Google Scholar 

  13. Blum R. H., Carter, S. K., Agre, K.; A clinical review of bleomycin: a new antineoplastic agent. Cancer 31, 903–913(1973).

    Article  PubMed  CAS  Google Scholar 

  14. Bonadonna G., De Lena, M., Monfardini, S., Bartoli, C., Bajetta, E., Baretta, G., Fossati- Bellani, F.: Clinical trials with bleomycin in lymphomas and solid tumors. Eur. J. Cancer 8,205–215 (1972)

    PubMed  CAS  Google Scholar 

  15. Bonadonna G., Lattuada, A., Banfi, A.: Recent trends in the treatment of non-Hodgkin’s lymphomas. Eur. J. Cancer 12, 661–673 (1975)

    Google Scholar 

  16. Bonadonna G., Monfardini, S.: Chemotherapy of non-Hodgkin’s lymphomas. Cancer Treat. Rev. 1, 167–181 (1974)

    Google Scholar 

  17. Bonadonna G., Zucalli, R., Monfardini, S., De Lena, M., Vslenghi, C.: Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 36, 252–259 (1975)

    Article  PubMed  CAS  Google Scholar 

  18. Cabanillas F., Rodriguez, V., Bodey, G. P., Benjamin, R. S.: Phase I-II study of maytansine (NSC 153,858). Proc. AACR and ASCO 18, 206 (AACR abstr. 823) (1977)

    Google Scholar 

  19. Capizzi R. L.: Improvement in the therapeutic index of methotrexate (NSC 740) by l-asparaginase (NSC 109229). Cancer Chemother. Rep. 6 (3), 37 1 (1975)

    CAS  Google Scholar 

  20. Carbone P. P., Kaplan, H. S., Musshof, K., Smithers, D. W., Tubiana, M.: Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 31, 1860–1861 (1971)

    PubMed  CAS  Google Scholar 

  21. Carbone P. P., Spurr, C.: Management of patients with malignant lymphoma. A comparative study of cyclophosphamide and vinca alkaloids. Cancer Res. 28, 811–822 (1968)

    PubMed  CAS  Google Scholar 

  22. Chabner B. A., Johnson, R. E., Young, R. C., Canellos, G. P., Hubbard, S. P., De Vita, V. T., Jr.: Sequential nonsurgical and surgical staging in non-Hodgkin’s lymphoma. Ann. Intern. Med.85, 149–154 (1976)

    PubMed  CAS  Google Scholar 

  23. Chabner B., Levine, A., Adamson, R., Johnson, B., Whangpeng, J., Young, R.: Initial clinical and pharmacological studies of maytansine. Proc. AACR and ASCO 18, 129 (AACR abstr. 515) (1977)

    Google Scholar 

  24. Corbett T. H., Griswold, D. P.: Treatment of colon adencarcinomas in mice with anguidine (NSC-141537) and anguidine+ 5 -FU (NSC-19893). Proc. AACR and ASCO 18, 115 (AACR abstr. 457)(1977)

    Google Scholar 

  25. Creaven P. J., Allen, L. M., Cohen, M. H., Nelson, R. L.; Studies on the clinical pharmacology and toxicology of isophosphamide (NSC 109724). Cancer Treat. Rep. 60, 445–449 (1976)

    PubMed  CAS  Google Scholar 

  26. Dawkins A. W., Grove, J. F., Tidd, B. K.: Diacetoxyscirpenol and some related compounds. Chem. Community 2, 27 (1965)

    Google Scholar 

  27. Djerassi I,. Kim, J. S.: Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin’s lymphomas) prolonged unmaintained remission. Cancer 38, 1043–1051

    Google Scholar 

  28. Durant J. R., Gams, R. A., Bartolucci, A. A., Dorfman, R. F.: BCNU 1with and without COP and cycle active therapy in non-Hodgkin’s lymphoma. Cancer Treat. Rep. (in press, 1977)

    Google Scholar 

  29. Ennis H. L., Moller, L., Wang, J. J., Selawry, O. S.: 2,3-dihydro-lH-imidazo (l,2-b)-pyrazole. A new inhibitor of deoxyribonucleic acid synthesis. Biochem. Pharmacol 20, 2639–2646 (1971)

    Article  PubMed  CAS  Google Scholar 

  30. European Organization for Research on the Treatment of Cancer, Co-operative Group for Leukaemias and Haematosarcomas: Clinical Screening of epipodophyllotoxin VM 26 in malignant lymphomas and solid tumours. Br. Med. J. 2, 744–748 (1972)

    Google Scholar 

  31. Edzinli E., Pocock, S., Berard, C. W., Aungst, C. W., Silverstein, M., Horton, J., Bennett, J., Bakemeier, R., Stolbach, L., Perlia, C., Brunk, S. F., Lenhard, R. E., Klaasen, D. J., Richter, O., Carbone. P.: Comparison of intensive versus moderate chemotherapy of lymphocytic lymphomas. Cancer 38,1060–1068 (Sept. 1976)

    Article  Google Scholar 

  32. Falkson H. C., Falkson, G.: Phase II trial of cytembena in patients with advanced ovarian and breast cancer. Cancer Treat. Rep. 60 (11), 1655–1658 (1976)

    PubMed  CAS  Google Scholar 

  33. Flannery E. P., Corder, M. P., Sheehan, W. W., Bateman, J. R.: Phase II evaluation of ICRF- 159 (NSC-129943) in non-Hodgkin’s lymphomas. Proc. AACR and ASCO 17, 289 (ASCO abstr. C- 209)(1976)

    Google Scholar 

  34. Frei E., III, Luce, J. K., Talley, R. W., Vaitkevicius, V. K., Wilson, H. E. 5 (3,3 dimethyl- triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. Cancer Chemother. Rep. 56, 667–670 (1972)

    PubMed  Google Scholar 

  35. Gottlieb J. A., Luce, J. K. Treatment of malignant melanoma with campothecin (NSC 100880). Cancer Chemother. Rep. 56, 103 (1972)

    PubMed  CAS  Google Scholar 

  36. Green D., Sallan, S., Krishan, A.: Single dose actinomycin D in relapsed childhood leukemia. Proc. AACR and ASCO 18, 302 1977 (ASCO abstr. C-144)

    Google Scholar 

  37. Griffin R. L., Comis, R. L., Lokich, J., Canellos, G.: Neocarzinostatin: phase I study. Proc. AACR and ASCO 18, 302 (ASCO abstr. C-142) (1977)

    Google Scholar 

  38. Haas C., Goodwin, W., Leite, C., Stephens, R., Hoogstraten, B.: Phase I study of anguidine diacetoxyscirpenol (NSC 141537). Proc. AACR and ASCO 18, 296 (ASCO abstr. C-120) (1977)

    Google Scholar 

  39. Haas C. D., Stephens, R. L., Hollister, M., Hoogstraten, B.: Phase I evaluation of dianhydrogalactitol (NSC 132313). Cancer Treat. Rep. 60, 611–614 (1976)

    PubMed  CAS  Google Scholar 

  40. Hayes D., Cvitkovic, E., Golbey, R., Scheiner, E., Krakoff, I. H.: Amelioration of renal toxicity of high dose eis platinum diammine dichloride (CPPD) by mannitol induced diuresis. Proc. AACE and ASCO 17, 169 (1976)

    Google Scholar 

  41. Helman L., Henney, J., Slavik, M.: Clinical brochure—anguidine (NSC 141537). Investigational Drug Branch Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.

    Google Scholar 

  42. Helman L., Henney, J., Slavik, M. Clinical brochure—Maytansine(NSC 153858). Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.

    Google Scholar 

  43. Hill J. M., Loeb, E., Pardue, A. S., Khan, A., Hill, N. O., King, J. J., Hill, R. W.: Platinum coordination compounds in the treatment of acute leukemia and other malignant diseases with particular reference to malanato 1,2-di-aminocyclohexane platinum (II). J. Clin. Haematol Oncology 7, 681–700 (1977)

    Google Scholar 

  44. Hoth D., Schein, P., McDonald, J., Buscaglia, D., Haller, D.: Phase I trial and clinical pharmacology of chlorozotocin (CL 2). Proc. AACR and ASCO 18, 309 (1977)

    Google Scholar 

  45. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.: Ara-C-analogues. In: Minutes of New Drug Liaison Meeting 186–242 (Feb. 17–18, 1977)

    Google Scholar 

  46. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.: Vindesine. In: Minutes of New Drug Liaison Meeting (Feb. 17–18,1977)

    Google Scholar 

  47. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.: Pyrazolo imidazole. In: Minutes of the Phase I Working Group Meeting (Oct. 7,1976)

    Google Scholar 

  48. Israel M., Modest, E. J., Frei, E., Ill: N-trifluoroacetyl adriamycin-14-valerate—an analogue with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res. 35,1365–1368 (1975)

    PubMed  CAS  Google Scholar 

  49. Jacobs E. M., Peters, F. C., Luce, J. K., Et Al: Mechlorethiamine (HCL) and cyclophosphamide in the treatment of Hodgkin’s disease and the lymphomas. JAMA 203, 392–398 (1969)

    Article  Google Scholar 

  50. Jacquillat Cl., Weill, M., Geman-Auclerc, M. F., Izrael, V., Bussed, A., Boiron, M., Bernard, T.: Clinical study of rubidazone (22050 R. P.), a new daunorubicin-derived compound, in 170 patients with leukemias and other malignancies. Cancer 37,653–659 (1976)

    Article  PubMed  CAS  Google Scholar 

  51. Jacquillat Cl., Weil, M., Geman, M. F., Izrael, V., Schaison, G., Boiron, M., Bernard, J.: Treatment of acute myeloblasts leukemia with R.P. 22050. Br. Med. J. 4,468–469 (1972)

    Article  PubMed  CAS  Google Scholar 

  52. Jones S. E., Fuks, Z., Bull, M., Kadin, M., Dorfam, R., Kaplan, H. S., Rosenberg, S. A.: Non- Hodgkin’s lymphomas IV—clinicopathologic correlation in 405 cases. Cancer 31, 806–823 (1973)

    Article  PubMed  CAS  Google Scholar 

  53. Jones S. E., Salmon, S., Members of the Southwest Oncology Group: Phase II trial of piperazinedione (Crystal-line antibiotic) in lymphoma and multiple myeloma. Proc. AACR and ASCO17,45 (AACR abstr. 179) (1976)

    Google Scholar 

  54. Jones S. E., Salmon, S. E., Moon, T. E., s, Members of the Southwest Oncology Group (Swog): Chemo-immunotherapy of non-Hodgkin’s lymphoma (NHL). Proc. AACR and ASCO 18, 291 (ASCO abstr. C-100) (1977)

    Google Scholar 

  55. Jones S. E., Rosenberg, S. A., Kaplan, H. S., Kadin, M. E., Dorfman, R. F.: Non-Hodgkin’s lymphomas II. Single agent chemotherapy. Cancer 30, 31–38 (1972)

    Article  PubMed  CAS  Google Scholar 

  56. Kaufman J. H., Ezdinli, E., Aungst, C. W., Stutzman, L.: Lymphosarcoma—a comparison of extended to conservative chemotherapy. Cancer 37,1283–1292 (1976)

    Article  PubMed  CAS  Google Scholar 

  57. Kaufman J. H., Hanjina, G. L., Mittleman, A., Aungst, C. W., Murphy, G. P.: Study of LEO 1031 (NSC 134087) in lymphocytic lymphoma and chronic lymphocytic leukemia. Cancer Treat. Rep. 60,277–279 (1976)

    CAS  Google Scholar 

  58. Kaufman J. H., Mittleman, A.: Clinical phase I trial of imosine dialdehyde (NSC 118954). Cancer Chemother. Rep. 59, 1007–1014 (1975)

    CAS  Google Scholar 

  59. Kennedy B. J., Hill, J., Bloomfield, C. D., Kiang, D., Fortuny, I., Theologides, A.: Combination (COP) versus successive single agent chemotherapy (C-O-P) in lymphocytic lymphoma. Proc. AACR and ASCO 16, 142 (AACR abstr. 568) (1975)

    Google Scholar 

  60. Krishan A., Frei, E., III, Paika, K,: Studies on the biological action of adriamycin analog, N- trifluoro-acetyl-adriamycin (AD 32). Proc. AACR and ASCO 18, 188 (AACR abstr. 751) (1977)

    Google Scholar 

  61. Laszlo J., Durant, J., Loeb, V.: Clinical pharmacological study of l-acetyl-2-picolinoylhydrazine (NSC 68626). Cancer Chemother. Rep. 53, 131–134 (1969)

    PubMed  CAS  Google Scholar 

  62. Lauria F., Baccarani, M., Fiacchini, M.: Methotrexate cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin’s lymphoma. Eur. J. Cancer 11, 343–349 (1975)

    PubMed  CAS  Google Scholar 

  63. Legha S. S., Slavik, M., Carter, S. K.: Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer 38, 27–35 (1976)

    Article  PubMed  CAS  Google Scholar 

  64. Legha S. S., Von Hoff, D. D., Slavik, M., Muggia, F. M.: Neocarzinostatin (NSC 157365)—a new cancerostatic compound. Oncology 33, 265–270 (1976)

    Article  PubMed  CAS  Google Scholar 

  65. Lenaz L., Page, J. A.: Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat. Rev. 3, 111–120 (1976)

    Article  CAS  Google Scholar 

  66. Lenhard R. E., Jr., Prentice, R. L., Owens, A. H., Jr., Bakmeier, R., Horton, J. H., Shnider, B. I., Stolbach, L., Berard, C. W., Carbone, P.: Combination chemotherapy of the malignant lymphomas—a controlled clinical trial. Cancer 38, 1052–1059 (1976)

    Article  PubMed  Google Scholar 

  67. Lias L. L., Kupchan, S. M., Horwitz, S. B.: Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis. Mol. Pharmacol. 12, 167–176 (1976)

    Google Scholar 

  68. Livingston R. B., Carter, S. K.: Single agents in cancer chemotherapy. New York-Washington- London: IFI/Plenum, 1970, p. 405

    Google Scholar 

  69. Mathé, G., Schwarzenberg, P., Pouillart, R., Oldham, R., Weiner, R., Jasmin, C., Rosenfeld, C., Hayat, M., Misset, J. L., Musset, M., Schneider, M., Amiel, J. L., De Vassal, F.: Two épipodophyllotoxin deratives, VN 26 and VP 16213, in the treatment of leukemias, hématosarcomas, and lymphomas. Cancer 34 (4), 985–992 (1974)

    Article  PubMed  Google Scholar 

  70. Mathé, G., Schwartzenberg, P., Pouillart, P., Weiner, R., Oldham, R., Jasmin, C., Rosenfeld, C., Hayat, M., Schneider, M., Amiel, J. L., Céoara, B., Steresco-Musset, M., De Vassal, F.: Essai de traitment de divers hématosarcomes par le 4-déméthyl-épipodophyllotoxine ß D. thénylidème glucoside (VM 26 ou EPT). Nouve. Presse Med. 23, 447 51 (1974)

    Google Scholar 

  71. Mathé, G., Schwartzenbergerg, P., Pouillart, P., Weiner, R., Oldham, R., Jasmin, C., Rosenfeld, C., Hayat, M., Schneider, M., Amiel, J. L., Céoara, B., Steresco-Musset, M., De Vassal, F.: Leucémies aiguës et hématosarcomes divers. Essai de traitement par un second dérivé de la podophyllotoxine (le 4-demethyl-epipodophyllotoxine beta.D. ethylidene glucoside VP 16213 ou EPE). Nouv. Presse Med. 2, 521–524 (1974)

    Google Scholar 

  72. McKelvey E. M.: Gallium nitrate in minutes of the phase I working group meeting, April 26–27, 1977. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md.

    Google Scholar 

  73. McKelvey E. M., Gottlieb, J. A., Wilson, H. E., Haut, A., Talley, R. W., Stephens, R., Lane, M., Gamble, J. F., Jones, S. E., Grozea, P. N., Gutterman, J., Coltman, C., Jr., Moon, T.: Hydroxyldaunomycin (adriamycin combination chemotherapy in malignant lymphoma. Cancer 38 (4), 1484–1493, (1976)

    Article  PubMed  CAS  Google Scholar 

  74. Meyers G. E., McGuire, W., Young, R. C.: Adriamycin: amelioration of toxicity by a-tocopheral. Cancer Treat. Rep. 60, 961–962 (1976)

    Google Scholar 

  75. Misset J. L., Pouillart, P., Belpomme, L., Schwarzenberg, L., Delgado, M., Gil, M., Jasmin, C., Hayat, M., Mathé, G.: Combination chemotherapy with adriamycine, VM 26, cyclophosphamide and prednisone in lymphosarcoma and reticulosarcoma stage III and IV. Eur. J. Cancer 13, 411–414 (1977)

    PubMed  CAS  Google Scholar 

  76. Moertel C. G., Schutt, et al.: Phase II study of campothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56, 95 (1972)

    Google Scholar 

  77. Möller, T. R., Brandt, L., Könynes, I., Lindberg, L. G.: Therapeutic effects of Leo 1031, an alkylating corticosteroid ester in lymphoproliferative disorders—II lymphocytic lymphoma. Acta Med. Scand.197, 323–327 (1975)

    Article  PubMed  Google Scholar 

  78. Muggia F. M., Creaven, P. J., Hansen, H. H., Et Al; Phase I clinical trial of weekly and daily treatment with campothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother. Rep. 5(5,515–521 (1972)

    Google Scholar 

  79. O’connell, M. J., Silverstein, M. J., Silverstein, M. N., Kiely, J. M., White, W. L.: Pilot study of two adriamycin-based regimens in patients with advanced malignant lymphomas. Cancer Treat. Rep. 57,(1), 65–68 (1977)

    Google Scholar 

  80. O’bryan, R. M., Baker, L. H., Gottlieb, J. A., Rivkin, S. E., Balcerak, S. P., Grumet, G. N., Salmon, S. E., Moon, T. E., Hoogstraten, B.: Dose response evaluation of adriamycin in human neoplasia. Cancer 39, 1940–1948 (1977)

    Article  PubMed  Google Scholar 

  81. O’Bryan, R. M., Luce, J. K., Talley, R. W., Gottlieb, J. A., Baker, L. J., Bonadonna, G.: Phase II evaluation of adriamycin in human neoplasia. Cancer 32, 1–8 (1973)

    Article  PubMed  Google Scholar 

  82. Page R. H., Talley, R. W., Bukagiar, J.: The enhanced anti-tumor activity of cis-diammedichlo- roplatinum (II) against murine tumors when combined with other agents. J. Clin. Haematol. Oncology 7, 96–104 (1977)

    CAS  Google Scholar 

  83. Perevodchikova N. I., Gorbunova, V. A., Lichinitser, M. P., Borisov, V. I., Alekseev, N. A., Vygodskaya, L.: Phase I clinical trial of carminomycin in a new anthracycline antibiotic. Proc. AACR and ASCO (AACR abstr 437) 77, 110 (1976)

    Google Scholar 

  84. Pittman S., Frei, E., Ill: Weekly methotrexate citrovorum (MTX-CF) with alkalinization: tumor response in a phase II study. Proc. AACR and ASCO 18, 124 (AACR abstr. 494) (1977)

    Google Scholar 

  85. Portlock C. S., Rosenberg, S. A., Glatstein, E., Kaplan, H. S.: Treatment of advanced non- Hodgkin’s lymphomas with favorable histologies: Preliminary results of a prospective trial. Blood 47, 747–756 (1976)

    PubMed  CAS  Google Scholar 

  86. Rappaport H.: Tumors of the hematopoetic system. In: Atlas of Tumor Pathology, Sec. 3, Fasc. 8. Washington, D.C.: Armed Forces Institute of Pathology, 1966

    Google Scholar 

  87. Remillard S., Et Al: Antimitotic activity of the potent tumor inhibitor maytansine. Science 189, 1002–1005 (1975)

    Article  PubMed  CAS  Google Scholar 

  88. Rozencweig M., Von Hoff, D. D., Slavik, M., Muggia, F. M.: Cis-diamminedichloroplatinum II: a new anticancer drug with significant clinical activity. Ann. Intern. Med. 86, 803–812 (1977)

    PubMed  CAS  Google Scholar 

  89. Schein P. S., Chabner, B. A., Canellos, G. P., Young, R. C., Berard, C. W., De Vita, V. T., Jr.: Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin’s lymphomas. Blood 43, 181–190 (1974)

    PubMed  CAS  Google Scholar 

  90. Schein P. S., De Vita, V. T., Jr., Hubbard, S., Chabner, B. A., Canellos, G. P., Berard, C., Young, R. C.: Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) in the treatment of advanced diffuse histiocytic lymphoma. Ann. Intern. Med.85, 417–422 (1976)

    PubMed  CAS  Google Scholar 

  91. Schein P. S., O’Connell, M. J., Blom, J., Hubbard, S., Magrath, I. T., Bergevin, P., Wiernik, P. H., Ziegler, J. L., De Vita, V. T.: Clinical antitumor activity and toxicity of streptozotocin (NSC-85998) Cancer 34, 993–1000 (1974)

    PubMed  CAS  Google Scholar 

  92. Schein P. S., Panasci, L., Woolley, P. V., Anderson, T.: Pharmacology of chlorozotocin (NSC- 178248), a new nitrosourea antitumor agent. Cancer Treat. Rep. 60, 801–805 (1976)

    CAS  Google Scholar 

  93. Sieber S. M., Mead, J. A. R., Adamson, R. H.: Pharmacology of antitumor agents from higher plants. Cancer Treat. Rep. 60, 1127–1139 (1976)

    CAS  Google Scholar 

  94. Spear P. W., Patno, M. E.: A comparative study of the effectiveness of HN2 and cyclophosphamide in bronchogenic carcinoma, Hodgkin’s disease and lymphosarcoma. Cancer Chemother. Rep. 16, 413–415(1962)

    PubMed  CAS  Google Scholar 

  95. Stein T. S., Moran, E. M., Desser, R. K., Miller, J. B., Golomb, H. M., Ultman, J. E.: Combination chemotherapy of lymphomas other than Hodgkin’s disease. Ann. Intern. Med.81, 601 (1974)

    PubMed  CAS  Google Scholar 

  96. Stolinsky D. C., Jacobs, E. M., Irwin, L. E., Bateman, J. R.: Study of trimethylcolchicinic acid methyl ether d-tartrate (TMCA; NSC.-36354) in Hodgkin’s and non-Hodgkin’s lymphoma. Proc. AACR and ASCO 77, 237 (ASCO abstr. C-l) (1976)

    Google Scholar 

  97. Stitzman L., Ezdinli, E. Z., Stutzman, M. A.: Vinblastine sulfate vs. cyclophosphamide in the therapy of lymphoma. JAMA 195, 173–178 (1966)

    Google Scholar 

  98. Sutow W. W., Komp. D., Vietti, T. J., Pinkerton, D.: Clinical trials with l-acetyl-2- picolinoylhydrazine (NSC-68626) in children. Cancer Chemother. Rep. 59, 341–344 (1975)

    CAS  Google Scholar 

  99. Von Hoff, D. D., Rozencweig, M., Soper, W. T., Helman, L. J., Davis, H. L., Penta, J. S., Muggia, F. M.: Whatever happened to NSC ? Cancer Treat. Rep. 61, 759–768 (1977)

    Google Scholar 

  100. Weiss A. J., Metter, G. E., Fletcher, W. S., Wilson, W. L., Grage, R. B., Ramirez, G.; Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep. 60, 813–822 (1976)

    CAS  Google Scholar 

  101. Wilkinson P. M., Israel, M., Pegg, W. J., Frei, E., Ill: Comparative hepatobiliary metabolism and excretion of adriamycin (ADR) and n-tri-flouroacetyladriamycin-14-valerate (AD-32). Proc. AACR and ASCO 18, 188 (AACR abstr. 752) (1977)

    Google Scholar 

  102. Wilson W. L., Weiss, A. J., Frelich, R. W.: A phase III study in lung cancer comparing hexamethylmelamine with dibromodulcital. Oncology 31, 289–305 (1975)

    Article  Google Scholar 

  103. Winchell H. S., Sanchez, P. D., Watanabe, C. K., Hollander, L., Auger, H. O., McCrae, I.: Visualization of tumors in humans using 67Ga-citrate and the Auger whole-body scanner, scintillation camera and tomographic scanner. J. Nucl. Med.11, 459–466 (1970)

    PubMed  CAS  Google Scholar 

  104. Wollner N., Burchenal, J. H., Lieberman, P. H., Exelby, P., D’Angio, G. J., Murphy, M. L.: Non Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer 37, 123–134(1976)

    Article  PubMed  CAS  Google Scholar 

  105. Worzolla J. F., Kaiman, B. D., Johnson, B. M., Ramirez, G., Bryan, G. T.: Metabolism of hexamethylmelamine-ring C in rats and man. Cancer Res. 34, 2669–2674 (1974)

    Google Scholar 

  106. Yang S. S.: Rifamycin antibiotics: Inhibitors of Rauscher murine leukemia virus reverse transcriptase and of purified DNA polymerases from human normal and leukemic lymphoblasts. J. Natl. Cancer Inst. 49, 7–25 (1972

    PubMed  CAS  Google Scholar 

  107. Zbinden G., Brandle, E.: Toxicologic screening of daunorubicin (NSC 82151), adriamycin (NSC 123127) and their derivatives in rats. Cancer Chemother. Rep. 59, 707–715 (1975)

    CAS  Google Scholar 

Download references

Authors
  1. H. L. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut de Cancérologie et d’Immunogénétique, Hôpital Paul-Brousse, 14-16, Avenue Paul-Vaillant-Couturier, F-94800, Villejuif, France

    Georges Mathé

  2. Laboratory of Immunochemistry and Immunopathology INSERM (U 108), and Laboratory of Cytology Research Institute on Blood Diseases, Hôpital Saint-Louis, 2, Place du Docteur-A. Fournier, F-75010, Paris, France

    Maxime Seligmann

  3. Department of Radiation, Institut Gustave-Roussy, 16bis, Avenue Paul-Vaillant-Couturier, F-94800, Villejuif, France

    Maurice Tubiana

Rights and permissions

Reprints and permissions

Copyright information

© 1978 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Davis, H.L., Von Hoff, D.D. (1978). Evaluation and Role of Single Chemotherapeutic Agents in Adult Non-Hodgkin’s Lymphoma. In: Mathé, G., Seligmann, M., Tubiana, M. (eds) Lymphoid Neoplasias II. Recent Results in Cancer Research, vol 65. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81249-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81249-1_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81251-4

  • Online ISBN: 978-3-642-81249-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation